Amylyx Pharmaceuticals Inc (AMLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 416 | -1,023 | 88,643 | 108,449 | 102,693 |
| Cost of Goods | 809 | 7,418 | 116,406 | 9,360 | 5,218 |
| Gross Profit | -393 | -8,441 | -27,763 | 99,089 | 97,475 |
| Operating Expenses | 76,077 | 68,263 | 94,773 | 97,515 | 78,973 |
| Operating Income | -75,661 | -76,286 | -122,130 | 1,934 | 18,720 |
| Other Income | 2,957 | 3,586 | 3,579 | 4,542 | 3,691 |
| Pre-tax Income | -72,704 | -72,700 | -118,551 | 6,476 | 22,411 |
| Income Tax | N/A | N/A | 242 | 1,745 | 1,518 |
| Net Income Continuous | -72,704 | -72,700 | -118,793 | 4,731 | 20,893 |
| Net Income | $-72,704 | $-72,700 | $-118,793 | $4,731 | $20,893 |
| EPS Basic Total Ops | -1.07 | -1.07 | -1.75 | 0.07 | 0.31 |
| EPS Basic Continuous Ops | -1.07 | -1.07 | -1.75 | 0.07 | 0.31 |
| EPS Diluted Total Ops | -1.07 | -1.07 | -1.75 | 0.07 | 0.30 |
| EPS Diluted Continuous Ops | -1.07 | -1.07 | -1.75 | 0.07 | 0.30 |
| EPS Diluted Before Non-Recurring Items | -0.53 | -0.73 | -0.46 | 0.07 | 0.30 |
| EBITDA(a) | $-77,745 | $-79,256 | $-124,397 | $-337 | $16,540 |